Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Mallinckrodt
Baxter
Merck
Teva
Novartis
Chinese Patent Office
Covington
Citi
Julphar

Generated: October 19, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,136,799

« Back to Dashboard

Which drugs does patent 6,136,799 protect, and when does it expire?


Patent 6,136,799 protects ZEMPLAR and is included in one NDA. There have been three Paragraph IV challenges on Zemplar.

Protection for ZEMPLAR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifteen patent family members in ten countries.

Summary for Patent: 6,136,799

Title: Cosolvent formulations
Abstract:Stable pharmaceutical formulations of a therapeutic agent, a low molecular weight alcohol and a glycol derivative are disclosed. Preferred formulations include 19-nor-1.alpha.,3.beta.,25-trihydroxy-9,10-secoergosta-5,7(E),22(E)-triene .
Inventor(s): Li; Lukchiu (Vernon Hills, IL), Pec; Edward Anthony (Brookfield, IL), Robinson; Daniel H. (Lake Bluff, IL), Stephens; Dennis A. (Mt. Prospect, IL), Jantzi; Kathee (Madison, WI), May; Thomas Barton (Grayslake, IL), Oberdier; John Paul (Gurnee, IL)
Assignee: Abbott Laboratories (Abbott Park, IL)
Application Number:09/057,143
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Formulation; Process;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Abbvie
ZEMPLAR
paricalcitol
SOLUTION;INTRAVENOUS020819-002Feb 1, 2000APRXYesYes► Subscribe► SubscribeY
Abbvie
ZEMPLAR
paricalcitol
SOLUTION;INTRAVENOUS020819-001Apr 17, 1998APRXYesYes► Subscribe► SubscribeY
Abbvie
ZEMPLAR
paricalcitol
SOLUTION;INTRAVENOUS020819-003Feb 1, 2000APRXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,136,799

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,361,758 Cosolvent formulations► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,136,799

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Portugal1073467► Subscribe
Japan2016053046► Subscribe
Japan5887368► Subscribe
Japan2014129360► Subscribe
Japan5548079► Subscribe
Japan2011037860► Subscribe
Japan4664499► Subscribe
Japan2002510652► Subscribe
Spain2229693► Subscribe
European Patent Office1073467► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Novartis
Colorcon
Chinese Patent Office
Argus Health
Moodys
Chubb
Cipla
Deloitte
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot